EpiCept's LidoPAIN, an analgesic pain therapy patch, failed a Phase III trial in Europe. According to researchers, LidoPAIN SP "did not achieve a statistically significant effect relative to placebo with respect to the primary endpoint of self-assessed pain intensity between 4 and 24 hours. In addition, a statistically significant effect was not achieved in the trial's co-primary endpoint of patient use of "rescue" medications, i.e. systemically-delivered analgesics used to alleviate pain." EpiCept secured a $10 million loan a week ago. Endo Pharmaceuticals has signed on as a commercialization partner for LidoPAIN.
- see the release on LidoPAIN